SAGE PRO

Home / Research / Emami Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Emami Limited — Q2 FY27 Results Analysis

Group sales grew 36.2%

Published · Quarter Q2 FY27 · EMAMILTD

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 consolidated revenue

Q2 FY26₹798.5 crore
Q2 FY27₹1,087.7 crore
CHART 2

Q2 EBITDA

Q2 FY26₹178.5 crore
Q2 FY27₹222.3 crore
CHART 3

Q2 EBITDA margin

Q2 FY2622.4%
Q2 FY2720.4%
CHART 4

Q2 PAT

Q2 FY26₹148.3 crore
Q2 FY27₹145.5 crore
ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Group sales grew 36.2%

Q2 consolidated revenue was 798.5 ₹ crore (Q2 FY26) versus 1087.7 ₹ crore (Q2 FY27). Group sales grew 36.2%.

Watch: Distinguish organic and acquired

RESEARCH INSIGHT

EBITDA increased 24.5%

Q2 EBITDA was 178.5 ₹ crore (Q2 FY26) versus 222.3 ₹ crore (Q2 FY27). EBITDA increased 24.5%.

Watch: Watch input inflation

RESEARCH INSIGHT

Margin contracted two points

Q2 EBITDA margin was 22.4 % (Q2 FY26) versus 20.4 % (Q2 FY27). Margin contracted two points.

Watch: Assess acquisition mix

RESEARCH INSIGHT

PAT declined despite EBITDA growth

Q2 PAT was 148.3 ₹ crore (Q2 FY26) versus 145.5 ₹ crore (Q2 FY27). PAT declined despite EBITDA growth.

Watch: Reconcile tax

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Quarter ended 30 September 2026 · Stance WATCH · Issuer-sourced. Emami's Q2 FY27 consolidated operating revenue of ₹1,087.7 crore was up 36.2%, but raw materials rose 60.7% and EBITDA margin slipped from 22.4% to 20.4%. Reported PAT declined from ₹148.3 crore to ₹145.5 crore, despite EBITDA increasing from ₹178.5 crore to ₹222.3 crore. This contrast reflects tax and other below-EBITDA effects and warns against equating acquisition-aided growth with per-share earnings. WATCH until gross margin and cash returns stabilize. [S1][S2]

Investment evidenceEarlier periodLatest period
Q2 consolidated revenue798.5 ₹ crore (Q2 FY26)1087.7 ₹ crore (Q2 FY27)
Q2 EBITDA178.5 ₹ crore (Q2 FY26)222.3 ₹ crore (Q2 FY27)
Q2 EBITDA margin22.4 % (Q2 FY26)20.4 % (Q2 FY27)
Q2 PAT148.3 ₹ crore (Q2 FY26)145.5 ₹ crore (Q2 FY27)
Q2 raw material cost231.4 ₹ crore (Q2 FY26)371.7 ₹ crore (Q2 FY27)
Q2 advertising & promotion156.4 ₹ crore (Q2 FY26)215.7 ₹ crore (Q2 FY27)
Q2 staff cost121.2 ₹ crore (Q2 FY26)140.1 ₹ crore (Q2 FY27)
Q2 PBT150.2 ₹ crore (Q2 FY26)193.6 ₹ crore (Q2 FY27)

Six relevant takeaways: Q2 consolidated revenue: Group sales grew 36.2%. Q2 EBITDA: EBITDA increased 24.5%. Q2 EBITDA margin: Margin contracted two points. Q2 PAT: PAT declined despite EBITDA growth. Q2 raw material cost: Input cost growth was substantial. Q2 advertising & promotion: Brand support spending grew. The separate sourced graphical Investment Briefing precedes the seven-chapter analysis.

Chapter 1 — Thirty-second decision and valuation burden

Emami's Q2 FY27 consolidated operating revenue of ₹1,087.7 crore was up 36.2%, but raw materials rose 60.7% and EBITDA margin slipped from 22.4% to 20.4%. Reported PAT declined from ₹148.3 crore to ₹145.5 crore, despite EBITDA increasing from ₹178.5 crore to ₹222.3 crore. This contrast reflects tax and other below-EBITDA effects and warns against equating acquisition-aided growth with per-share earnings. WATCH until gross margin and cash returns stabilize. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 consolidated revenue: 1087.7 ₹ crore (Q2 FY27) versus 798.5 ₹ crore (Q2 FY26). Group sales grew 36.2%; Distinguish organic and acquired. [S2]
  • Q2 EBITDA: 222.3 ₹ crore (Q2 FY27) versus 178.5 ₹ crore (Q2 FY26). EBITDA increased 24.5%; Watch input inflation. [S2]
  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 22.4 % (Q2 FY26). Margin contracted two points; Assess acquisition mix. [S2]

Investor interpretation. Group sales grew 36.2%. The practical test is to distinguish organic and acquired. EBITDA increased 24.5%. The practical test is to watch input inflation. Margin contracted two points. The practical test is to assess acquisition mix. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 2 — Reported quarter and H1 earnings quality

The issuer explained that reported domestic Q2 growth and like-for-like growth differ because of previous-year inclusion of Axiom Ayurveda and IncNut Digital. Domestic growth was presented as about 49% reported versus 32% comparable, while international business declined about 2%. The reported Q2 PAT decline of about 1.9% contrasts with nearly 29% PBT growth. The income statement shows tax expense rising from ₹1.8 crore to ₹48.1 crore, influenced by MAT credit movements. Those are not direct reflections of branded operating quality. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 22.4 % (Q2 FY26). Margin contracted two points; Assess acquisition mix. [S2]
  • Q2 PAT: 145.5 ₹ crore (Q2 FY27) versus 148.3 ₹ crore (Q2 FY26). PAT declined despite EBITDA growth; Reconcile tax. [S2]
  • Q2 raw material cost: 371.7 ₹ crore (Q2 FY27) versus 231.4 ₹ crore (Q2 FY26). Input cost growth was substantial; Track pricing. [S2]

Investor interpretation. Margin contracted two points. The practical test is to assess acquisition mix. PAT declined despite EBITDA growth. The practical test is to reconcile tax. Input cost growth was substantial. The practical test is to track pricing. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 3 — Business segments, products and customer economics

Emami's products include BoroPlus and skincare, Navratna and Kesh King hair/scalp care, Zandu health products, menthol and pain-management franchises, along with newly acquired and invested brands. Q2 category net sales in the presentation were roughly ₹194 crore hair/scalp, ₹191 crore skincare, ₹284 crore health care and ₹239 crore strategic investments, with international business at ₹171 crore. These categories carry different distribution and promotional economics; their reported growth should not be mistaken for identical organic volume growth. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 raw material cost: 371.7 ₹ crore (Q2 FY27) versus 231.4 ₹ crore (Q2 FY26). Input cost growth was substantial; Track pricing. [S2]
  • Q2 advertising & promotion: 215.7 ₹ crore (Q2 FY27) versus 156.4 ₹ crore (Q2 FY26). Brand support spending grew; Measure marketing returns. [S2]
  • Q2 staff cost: 140.1 ₹ crore (Q2 FY27) versus 121.2 ₹ crore (Q2 FY26). Personnel expenses increased; Track productivity. [S2]

Investor interpretation. Input cost growth was substantial. The practical test is to track pricing. Brand support spending grew. The practical test is to measure marketing returns. Personnel expenses increased. The practical test is to track productivity. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 4 — Management milestones and analyst challenges

Management discussed FromMaa baby products, scalp-care extensions, sun care, and activations behind heritage brands. Skin-care growth was 31% and hair/scalp care 30%, but health-care growth was only 11%; international Q2 growth was negative 2%. Growth in marketing and product innovation can raise consumer frequency, yet must be measured against ₹215.7 crore Q2 advertising/promotional spending, up from ₹156.4 crore. Analyst questions should address repeat consumers, acquisition integration, online economics and category contribution. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 staff cost: 140.1 ₹ crore (Q2 FY27) versus 121.2 ₹ crore (Q2 FY26). Personnel expenses increased; Track productivity. [S2]
  • Q2 PBT: 193.6 ₹ crore (Q2 FY27) versus 150.2 ₹ crore (Q2 FY26). PBT increased about 29%; Compare taxation. [S2]
  • Q2 tax expense: 48.1 ₹ crore (Q2 FY27) versus 1.8 ₹ crore (Q2 FY26). Tax changed materially as MAT credits moved; Reconcile statutory items. [S2]

Investor interpretation. Personnel expenses increased. The practical test is to track productivity. PBT increased about 29%. The practical test is to compare taxation. Tax changed materially as MAT credits moved. The practical test is to reconcile statutory items. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 5 — Cash conversion, capex, debt and capital returns

Raw materials were ₹371.7 crore versus ₹231.4 crore, while advertising rose to ₹215.7 crore from ₹156.4 crore. The quarter's EBITDA improved even as gross margin pressured; however PAT was ₹145.5 crore versus ₹148.3 crore due to below-operating charges, notably a tax-base change. Before attributing a premium valuation to the growth platform, examine working capital, goodwill/intangibles amortization, acquisition cost and actual free cash flow. The accepted source pair does not provide a fully supported discounted-cash-flow model. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 tax expense: 48.1 ₹ crore (Q2 FY27) versus 1.8 ₹ crore (Q2 FY26). Tax changed materially as MAT credits moved; Reconcile statutory items. [S2]
  • H1 revenue: 2126.9 ₹ crore (H1 FY27) versus 1702.6 ₹ crore (H1 FY26). Half-year group sales increased; Compare like-for-like. [S2]
  • H1 EBITDA: 448.5 ₹ crore (H1 FY27) versus 392.7 ₹ crore (H1 FY26). H1 EBITDA grew slower than sales; Watch six-month margin. [S2]

Investor interpretation. Tax changed materially as MAT credits moved. The practical test is to reconcile statutory items. Half-year group sales increased. The practical test is to compare like-for-like. H1 EBITDA grew slower than sales. The practical test is to watch six-month margin. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 6 — Conditional bull/base/bear and falsification tests

Bull conditions: acquired and mature brands retain profitable new buyers, raw-material inflation is passed through, healthcare improves and EBITDA margin recovers from 20.4%. Base conditions: domestic sales stay healthy while promotional spend and acquisitions cap operating leverage. Bear conditions: inflation, lower rural demand, discounting, poor integration economics or unexpected tax cash outflows erode earnings conversion. A market-price target or probability-weighted return is not provided without current valuation evidence. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 consolidated revenue: 1087.7 ₹ crore (Q2 FY27) versus 798.5 ₹ crore (Q2 FY26). Group sales grew 36.2%; Distinguish organic and acquired. [S2]
  • Q2 EBITDA: 222.3 ₹ crore (Q2 FY27) versus 178.5 ₹ crore (Q2 FY26). EBITDA increased 24.5%; Watch input inflation. [S2]
  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 22.4 % (Q2 FY26). Margin contracted two points; Assess acquisition mix. [S2]

Investor interpretation. Group sales grew 36.2%. The practical test is to distinguish organic and acquired. EBITDA increased 24.5%. The practical test is to watch input inflation. Margin contracted two points. The practical test is to assess acquisition mix. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Chapter 7 — Quarterly monitoring and investor action plan

WATCH Q2 consolidated revenue ₹1,087.7 crore, EBITDA ₹222.3 crore, PAT ₹145.5 crore, raw-material cost ₹371.7 crore and tax expense ₹48.1 crore. Track reported and like-for-like domestic growth separately from international declines, as well as H1 revenue ₹2,126.9 crore. Upgrade only on sustained cash-margin stabilization and repeat purchase in newer brands; downgrade if sales grow while tax-adjusted net earnings and cash shrink. [S1][S2]

Numbers, implications and monitoring triggers

  • Q2 EBITDA margin: 20.4 % (Q2 FY27) versus 22.4 % (Q2 FY26). Margin contracted two points; Assess acquisition mix. [S2]
  • Q2 PAT: 145.5 ₹ crore (Q2 FY27) versus 148.3 ₹ crore (Q2 FY26). PAT declined despite EBITDA growth; Reconcile tax. [S2]
  • Q2 raw material cost: 371.7 ₹ crore (Q2 FY27) versus 231.4 ₹ crore (Q2 FY26). Input cost growth was substantial; Track pricing. [S2]

Investor interpretation. Margin contracted two points. The practical test is to assess acquisition mix. PAT declined despite EBITDA growth. The practical test is to reconcile tax. Input cost growth was substantial. The practical test is to track pricing. Distinct reporting periods, sector units, reported and adjusted measures are preserved rather than merged into an unsupported forecast or valuation claim.

Original issuer/exchange documents and limits

[S1] Emami Limited Q2 FY27 earnings-call transcript — accepted management and investor evidence. [S2] — financial and operating exhibits.

No registry identifiers are displayed in investor prose or charts. Reported accounting measures and management forecasts retain their distinct basis. Source limitations prevent unsupported stock prices, guaranteed dividends, cash flows, debt or investment targets.

Additional company evidence

CHART 5

Q2 raw material cost

Q2 FY26₹231.4 crore
Q2 FY27₹371.7 crore
CHART 6

Q2 advertising & promotion

Q2 FY26₹156.4 crore
Q2 FY27₹215.7 crore
CHART 7

Q2 staff cost

Q2 FY26₹121.2 crore
Q2 FY27₹140.1 crore
CHART 8

Q2 PBT

Q2 FY26₹150.2 crore
Q2 FY27₹193.6 crore
SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.